GB Patent

GB2597281A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury

Assigned to GW Research Ltd · Expires 2022-01-26 · 4y expired

What this patent protects

A cannabidiol (CBD) preparation is disclosed for use in the treatment of seizures associated with rare epilepsy syndromes related to brain injury. In particular those which are experienced in patients diagnosed with hypoxic ischaemic encephalopathy (HIE) or anoxia at birth. In a …

USPTO Abstract

A cannabidiol (CBD) preparation is disclosed for use in the treatment of seizures associated with rare epilepsy syndromes related to brain injury. In particular those which are experienced in patients diagnosed with hypoxic ischaemic encephalopathy (HIE) or anoxia at birth. In a further embodiment, the types of seizures include tonic, tonic-clonic, atonic, myoclonic, absence, focal seizures with impairment and spasms. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Drugs covered by this patent

Patent Metadata

Patent number
GB2597281A
Jurisdiction
GB
Classification
—
Expires
2022-01-26
Drug substance claim
No
Drug product claim
No
Assignee
GW Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.